Seqirus (owned by CSL) has joined an international, non-profit venture dedicated to decoding the immune system to develop a universal flu vaccine that affords long-lasting protection against seasonal and pandemic influenza across demographics and geography. The Human Vaccines Project aims to decode the human immune system to accelerate development of vaccines and immunotherapies against major…

Read More